Can ginger ameliorate chemotherapy-induced nausea? Protocol of a randomized double blind, placebo-controlled trial

BMC Complementary and Alternative Medicine

Liz Isenring⁵  Avni Sali⁶  Damien Thomson⁴  Daniel McKavanagh¹  Luis Vitetta³  Karin Ried⁶  Alexandra L McCarthy²  Wolfgang Marx⁶ 

[1] Oncology & Haematology Unit, Princess Alexandra Hospital, Brisbane, QLD, Australia;Institute of Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia;Medlab, Sydney, NSW, Australia;PAH Oncology & Haematology Unit, Princess Alexandra Hospital, Brisbane, QLD, Australia;Department of Nutrition & Dietetics, Princess Alexandra Hospital, Brisbane, QLD, Australia;National Institute of Integrative Medicine, Melbourne, VIC, Australia

关键词: Nausea;    CINV;    Ginger;   

Others  :  1220189
DOI  :  10.1186/1472-6882-14-134

 received in 2013-11-04, accepted in 2014-02-14,  发布年份 2014

【 摘 要 】

Background

Preliminary research shows ginger may be an effective adjuvant treatment for chemotherapy-induced nausea and vomiting but significant limitations need to be addressed before recommendations for clinical practice can be made.

Methods/Design

In a double–blinded randomised-controlled trial, chemotherapy-naïve patients will be randomly allocated to receive either 1.2 g of a standardised ginger extract or placebo per day. The study medication will be administrated as an adjuvant treatment to standard anti-emetic therapy and will be divided into four capsules per day, to be consumed approximately every 4 hours (300 mg per capsule administered q.i.d) for five days during the first three cycles of chemotherapy. Acute, delayed, and anticipatory symptoms of nausea and vomiting will be assessed over this time frame using a valid and reliable questionnaire, with nausea symptoms being the primary outcome. Quality of life, nutritional status, adverse effects, patient adherence, cancer-related fatigue, and CINV-specific prognostic factors will also be assessed.

Discussion

Previous trials in this area have noted limitations. These include the inconsistent use of standardized ginger formulations and valid questionnaires, lack of control for anticipatory nausea and prognostic factors that may influence individual CINV response, and the use of suboptimal dosing regimens. This trial is the first to address these issues by incorporating multiple unique additions to the study design including controlling for CINV-specific prognostic factors by recruiting only chemotherapy-naïve patients, implementing a dosing schedule consistent with the pharmacokinetics of oral ginger supplements, and independently analysing ginger supplements before and after recruitment to ensure potency. Our trial will also be the first to assess the effect of ginger supplementation on cancer-related fatigue and nutritional status. Chemotherapy-induced nausea and vomiting are distressing symptoms experienced by oncology patients; this trial will address the significant limitations within the current literature and in doing so, will investigate the effect of ginger supplementation as an adjuvant treatment in modulating nausea and vomiting symptoms.

Trial registration

ANZCTR.org.au Identifier: ACTRN12613000120774.

【 授权许可】

   
2014 Marx et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB: Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005, 13:219-227.
• [2]Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D: Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002, 95:155-163.
• [3]Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J: Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006, 24:4472-4478.
• [4]Vidall C, Dielenseger P, Farrell C, Lennan E, Muxagata P, Fernandez-Ortega P, Paradies K: Evidence-based management of chemotherapy-induced nausea and vomiting: a position statement from a European cancer nursing forum. Ecancermedicalsci 2011, 5:211.
• [5]Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, Di Maio M, Andrea B, Deuson RR: The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 2007, 15:179-185.
• [6]Baliga MS, Haniadka R, Pereira MM, D'Souza JJ, Pallaty PL, Bhat HP, Popuri S: Update on the chemopreventive effects of ginger and its phytochemicals. Crit Rev Food Sci Nutr 2011, 51:499-523.
• [7]Holtmann S, Clarke AH, Scherer H, Hohn M: The anti-motion sickness mechanism of ginger. A comparative study with placebo and dimenhydrinate. Acta Otolaryngol 1989, 108:168-174.
• [8]Willetts KE, Ekangaki A, Eden JA: Effect of a ginger extract on pregnancy-induced nausea: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2003, 43:139-144.
• [9]Ernst E, Pittler MH: Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth 2000, 84:367-371.
• [10]Manusirivithaya S, Sripramote M, Tangjitgamol S, Sheanakul C, Leelahakorn S, Thavaramara T, Tangcharoenpanich K: Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer 2004, 14:1063-1069.
• [11]Sontakke S, Thawani V, Naik MS: Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: a randomized, cross-over, double blind study. Indian J Pharmacol 2003, 35:5.
• [12]Chrubasik S, Pittler MH, Roufogalis BD: Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. Phytomedicine 2005, 12:684-701.
• [13]Platel K, Srinivasan K: Influence of dietary spices or their active principles on digestive enzymes of small intestinal mucosa in rats. Int J Food Sci Nutr 1996, 47:55-59.
• [14]Yamahara J, Huang QR, Li YH, Xu L, Fujimura H: Gastrointestinal motility enhancing effect of ginger and its active constituents. Chem & Pharmaceutical bulletin 1990, 38:430-431.
• [15]Wu KL, Rayner CK, Chuah SK, Changchien CS, Lu SN, Chiu YC, Chiu KW, Lee CM: Effects of ginger on gastric emptying and motility in healthy humans. Eur J Gastroenterol Hepatol 2008, 20:436-440.
• [16]Riyazi A, Hensel A, Bauer K, Geissler N, Schaaf S, Verspohl EJ: The effect of the volatile oil from ginger rhizomes (Zingiber officinale), its fractions and isolated compounds on the 5-HT3 receptor complex and the serotoninergic system of the rat ileum. Planta Med 2007, 73:355-362.
• [17]Abdel-Aziz H, Windeck T, Ploch M, Verspohl EJ: Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol 2006, 530:136-143.
• [18]Dugasani S, Pichika MR, Nadarajah VD, Balijepalli MK, Tandra S, Korlakunta JN: Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J Ethnopharmacol 2010, 127:515-520.
• [19]Sharma SS, Kochupillai V, Gupta SK, Seth SD, Gupta YK: Antiemetic efficacy of ginger (Zingiber officinale) against cisplatin-induced emesis in dogs. J Ethnopharmacol 1997, 57:93-96.
• [20]Sharma SS, Gupta YK: Reversal of cisplatin-induced delay in gastric emptying in rats by ginger (Zingiber officinale). J Ethnopharmacol 1998, 62:49-55.
• [21]Marx WM, Teleni L, McCarthy AL, Vitetta L, McKavanagh D, Thomson D, Isenring E: Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: a systematic literature review. Nutr Rev 2013, 71:245-254.
• [22]Isenring E, Cross G, Kellett E, Koczwara B, Daniels L: Nutritional status and information needs of medical oncology patients receiving treatment at an Australian public hospital. Nutr Cancer 2010, 62:220-228.
• [23]Davidson W, Teleni L, Muller J, Ferguson M, McCarthy AL, Vick J, Isenring EA: Malnutrition and chemotherapy-induced nausea and vomiting: implications for practice. Oncol Nurs Forum 2012, 39:E340-345.
• [24]Van Cutsem E, Arends J: The causes and consequences of cancer-associated malnutrition. European J of Oncol nursing: the official J of European Oncol Nursing Soc 2005, 9:S51-S63.
• [25]Tong HT, Isenring EA, Yates P: The prevalence of nutrition impact symptoms and their relationship to quality of life and clinical outcomes in medical oncology patients. Support Care Cancer 2008, 17:83-90.
• [26]Annunziata MA, Muzzatti B, Mella S, Bidoli E: Fatigue, quality of life, and mood states during chemotherapy in Italian cancer patients. Tumori 2013, 99:e28-33.
• [27]Irvine D, Vincent L, Graydon JE, Bubela N, Thompson L: The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nurs 1994, 17:367-378.
• [28]Oh HS, Seo WS: Systematic review and meta-analysis of the correlates of cancer-related fatigue. Worldviews Evid Based Nurs 2011, 8:191-201.
• [29]Wood JM, Chapman K, Eilers J: Tools for assessing nausea, vomiting, and retching. Cancer Nurs 2011, 34:E14-24.
• [30]Rhodes VA, McDaniel RW: The index of nausea, vomiting, and retching: a new format of the lndex of nausea and vomiting. Oncol Nurs Forum 1999, 26:889-894.
• [31]Rubenstein EB: The Role of Prognostic Factors in Chemotherapy-Induced Nausea and Vomiting. In Management of Nausea and Vomiting in Cancer and Cancer Treatment. Edited by Hesketh PJ. Sudbury, MA: Jones and Bartlett; 2005:87-98.
• [32]Booth CM, Clemons M, Dranitsaris G, Joy A, Young S, Callaghan W, Trudeau M, Petrella T: Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 2007, 5:374-380.
• [33]Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, Patoia L, Santi E, Penza O, Ballatori E: Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Of Clin Oncol 1991, 14:238-242.
• [34]Roscoe JA, Morrow GR, Colagiuri B, Heckler CE, Pudlo BD, Colman L, Hoelzer K, Jacobs A: Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 2010, 18:869-876.
• [35]Morrow GR, Roscoe JA, Hickok JT, Stern RM, Pierce HI, King DB, Banerjee TK, Weiden P: Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park) 1998, 12:32-37.
• [36]Yu Y, Zick S, Li X, Zou P, Wright B, Sun D: Examination of the pharmacokinetics of active ingredients of ginger in humans. AAPS J 2011, 13:417-426.
• [37]Zick SM, Djuric Z, Ruffin MT, Litzinger AJ, Normolle DP, Alrawi S, Feng MR, Brenner DE: Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008, 17:1930-1936.
• [38]Zick SM, Turgeon DK, Vareed SK, Ruffin MT, Litzinger AJ, Wright BD, Alrawi S, Normolle DP, Djuric Z, Brenner DE: Phase II study of the effects of ginger root extract on eicosanoids in colon mucosa in people at normal risk for colorectal cancer. Cancer Prev Res (Phila) 2011, 4:1929-1937.
• [39]Schwertner HA, Rios DC, Pascoe JE: Variation in concentration and labeling of ginger root dietary supplements. Obstet Gynecol 2006, 107:1337-1343.
• [40]Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med 2008, 358:2482-2494.
• [41]BlueBonnet Nutrition http://www.bluebonnetnutrition.com/ webcite
• [42]Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT: Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992, 1:331-340.
• [43]Brearly SG, Clements CV, Molassiotis A: A review of patients self-report tools for chemotherapy-induced nausea and vomiting. Support Care Cancer 2008, 16:1213-1229.
• [44]Cohen L, de Moor C, Eisenberg P, Ming E, Hu H: Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007, 15:497-503.
• [45]Chang VT, Hwang SS, Feuerman M: Validation of the edmonton symptom assessment scale. Cancer 2000, 88:2164-2171.
• [46]Bauer J, Capra S, Ferguson M: Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr 2002, 56:779-785.
• [47]Cella D, Hahn EA, Dineen K: Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002, 11:207-221.
• [48]Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, et al.: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21:v232-v243.
• [49]Panahi Y, Saadat A, Sahebkar A, Hashemian F, Taghikhani M, Abolhasani E: Effect of Ginger on Acute and Delayed Chemotherapy-Induced Nausea and Vomiting: A Pilot. Open-Label Clinical Trial. Integr Cancer Ther: Randomized; 2012.
• [50]Zick S, Ruffin M, Lee J, Normolle D, Siden R, Alrawi S, Brenner D: Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer 2009, 17:563-572.
• [51]Ryan JL, Heckler CE, Roscoe JA, Dakhil SR, Kirshner J, Flynn PJ, Hickok JT, Morrow GR: Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer 2012, 20:1479-1489.
• [52]Pillai AK, Sharma KK, Gupta YK, Bakhshi S: Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer 2011, 56:234-238.
• [53]Arfeen Z, Owen H, Plummer JL, Ilsley AH, Sorby-Adams RA, Doecke CJ: A double-blind randomized controlled trial of ginger for the prevention of postoperative nausea and vomiting. Anaesth Intensive Care 1995, 23:449-452.
• [54]Lien HC, Sun WM, Chen YH, Kim H, Hasler W, Owyang C: Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. Am J Physiol Gastrointest Liver Physiol 2003, 284:G481-489.